BACKGROUNDDrug Discovery Collaboration Agreement • November 14th, 2001 • Array Biopharma Inc • Services-medical laboratories • Washington
DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • June 30th, 2014 • Loxo Oncology, Inc. • Pharmaceutical preparations • New York
This DRUG DISCOVERY COLLABORATION AGREEMENT (the “Agreement”), effective as of July 3, 2013 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), and Loxo Oncology, Inc., a Delaware corporation, having an address at c/o Aisling Capital, 888 7th Avenue, 30th Floor, New York, New York 10106 (“Loxo”).
ContractDrug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
David L. Snitman, Ph.D. Chief Operating Officer Array BioPharma, Inc. Boulder, CO 80301 RE: Amendment No. 6 to the Drug Discovery Collaboration Agreement Dear Dr. Snitman:Drug Discovery Collaboration Agreement • September 1st, 2006 • Array Biopharma Inc • Services-medical laboratories
As you know, InterMune, Inc. (“InterMune”) and Array BioPharma Inc. (“Array”) are parties to that certain Drug Discovery Collaboration Agreement dated September 13, 2002, as amended May 8, 2003, January 7, 2004, September 10, 2004, December 7, 2004 and June 30, 2005 (collectively, the “Agreement”). As we have previously discussed with you and/or John Moore, we would like to further amend the Agreement Accordingly, the parties agree that the Agreement is hereby amended as follows, effective as of January 1, 2006 (“Amendment Effective Date”):
February 3, 2006 VIA FAX AND FEDERAL EXPRESS David L. Snitman, Ph.D. Chief Operating Officer Array BioPharma, Inc. 3200 Walnut Street Boulder, CO 80301 RE: Amendment No. 6 to the Drug Discovery Collaboration Agreement Dear Dr. Snitman:Drug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
As you know, InterMune, Inc. (“InterMune”) and Array BioPharma Inc. (“Array”) are parties to that certain Drug Discovery Collaboration Agreement dated September 13, 2002, as amended May 8, 2003, January 7, 2004, September 10, 2004, December 7, 2004 and June 30, 2005 (collectively, the “Agreement”). As we have previously discussed with you and/or John Moore, we would like to further amend the Agreement. Accordingly, the parties agree that the Agreement is hereby amended as follows, effective as of January 1, 2006 (“Amendment Effective Date”):
ContractDrug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
SEVENTH AMENDMENT TO DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • May 7th, 2015 • Array Biopharma Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 7 (“Seventh Amendment”), effective as of the Settlement Effective Date (defined below) (“Amendment Date”), is entered into by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), (collectively, the “Parties” or individually, a “Party”).
DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations • Colorado
This DRUG DISCOVERY COLLABORATION AGREEMENT (the “Agreement”), effective as of September 13, 2002 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), and InterMune, Inc., a Delaware corporation, having a principal place of business at 3280 Bayshore Boulevard, Brisbane, California 94005 (“InterMune”).
SIXTH AMENDMENT TO DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • November 9th, 2010 • Array Biopharma Inc • Pharmaceutical preparations
This Amendment No. 6 (“Sixth Amendment”), effective as of September 30, 2010 (“Amendment Date”), is entered into by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), (collectively, the “Parties” or individually, a “Party”).
VIA FAX AND FEDERAL EXPRESS December 7, 2004 David L. Snitman, Ph.D. Chief Operating Officer Array BioPharma, Inc. 3200 Walnut Street Boulder, CO 80301 RE: Amendment No. 4 to the Drug Discovery Collaboration Agreement Dear Dr. Snitman:Drug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
As you know, InterMune, Inc. (“InterMune”) and Array BioPharma Inc. (“Array”) are parties to that certain Drug Discovery Collaboration Agreement dated September 13, 2002, as amended May 8, 2003, January 7, 2004 and September 10, 2004 (collectively, the “Agreement”). The parties agree that the Agreement is hereby amended as follows, effective as of the date of this letter (“Amendment Effective Date”):
DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • February 4th, 2015 • Array Biopharma Inc • Pharmaceutical preparations
THIS AMENDMENT NO.3 TO DRUG DISCOVERY COLLABORATION AGREEMENT (this "Amendment") effective as of October 13, 2014 (the "Amendment Date"), is made by and between Array BioPharma Inc., a Delaware corporation ("Array"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo").
July 30, 2009 Array BioPharma Inc. Boulder, Colorado 80301 Re: Drug Discovery Collaboration Agreement Ladies/Gentlemen:Drug Discovery Collaboration Agreement • November 2nd, 2009 • Array Biopharma Inc • Pharmaceutical preparations
Reference is made to that certain Drug Discovery Collaboration Agreement between Array BioPharma Inc. (“Array”) and Genentech, Inc. (“Genentech”), effective as of December 22, 2003, which was subsequently modified by a Letter Agreement, dated October 11, 2004, and amended by a First Amendment, dated May 20, 2005, a Second Amendment, dated October 1, 2005, a Third Amendment, dated April 2, 2007, a Fourth Amendment, dated July 25, 2008, and a Fifth Amendment, dated September 1, 2008 (collectively, the “Agreement”). All capitalized terms used in this letter agreement (“Letter Agreement”), which is effective as of January 29, 2009, shall have the meanings defined in the Agreement unless otherwise defined herein.
AMENDMENT NO. 5 TO DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • March 15th, 2016 • Loxo Oncology, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO.5 TO DRUG DISCOVERY COLLABORATION AGREEMENT (“Amendment”), effective February 18, 2016 (the “Amendment Date”), is by and between Array BioPharma Inc., a Delaware corporation (“Array”), and Loxo Oncology, Inc., a Delaware corporation (“Loxo”).
FOURTH AMENDMENT TO DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • November 4th, 2008 • Array Biopharma Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 4 (“Fourth Amendment”), effective as of July 25, 2008 (“Amendment Date”), is entered into by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), (collectively, the “Parties” or individually, a “Party”).
ARTICLE 1DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • August 12th, 2013 • Array Biopharma Inc • Pharmaceutical preparations • New York
This DRUG DISCOVERY COLLABORATION AGREEMENT (the “Agreement”), effective as of July 3, 2013 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), and Loxo Oncology, Inc., a Delaware corporation, having an address at c/o Aisling Capital, 888 7th Avenue, 30th Floor, New York, New York 10106 (“Loxo”).
AMENDMENT NO. 3 TO DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • March 27th, 2015 • Loxo Oncology, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO.3 TO DRUG DISCOVERY COLLABORATION AGREEMENT (this “Amendment”) effective as of October 13, 2014 (the “Amendment Date”), is made by and between Array BioPharma Inc., a Delaware corporation (“Array”), and Loxo Oncology, Inc., a Delaware corporation (“Loxo”).
August 31, 2006 VIA FAX AND FEDERAL EXPRESS David L. Snitman, Ph.D. Chief Operating Officer Array BioPharma, Inc.Drug Discovery Collaboration Agreement • November 6th, 2006 • Array Biopharma Inc • Pharmaceutical preparations
AMENDMENT NO. 4 TO DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • May 14th, 2015 • Loxo Oncology, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 4 TO DRUG DISCOVERY COLLABORATION AGREEMENT (this “Amendment”) effective as of March 31, 2015 (the “Amendment Date”), is made by and between Array BioPharma Inc., a Delaware corporation (“Array”), and Loxo Oncology, Inc., a Delaware corporation (“Loxo”).
DRUG DISCOVERY COLLABORATION AGREEMENT BETWEEN GENENTECH, INC. AND ARRAY BIOPHARMA INC.Drug Discovery Collaboration Agreement • February 2nd, 2004 • Array Biopharma Inc • Services-medical laboratories • New York
This Drug Discovery Collaboration Agreement (“Agreement”) is made and entered into, effective as of December 22, 2003 (“Effective Date”), by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), (collectively, the “Parties” or individually, a “Party”).
AMENDMENT NO. 1 TO DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • August 15th, 2014 • Array Biopharma Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO DRUG DISCOVERY COLLABORATION AGREEMENT (this “Amendment”) effective as of November 26, 2013 (the “Amendment Date”), is made by and between Array BioPharma Inc., a Delaware corporation (“Array”), and Loxo Oncology, Inc., a Delaware corporation (“Loxo”).
ContractDrug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • August 21st, 2015 • Array Biopharma Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 4 TO DRUG DISCOVERY COLLABORATION AGREEMENT (this “Amendment”) effective as of March 31, 2015 (the “Amendment Date”), is made by and between Array BioPharma Inc., a Delaware corporation (“Array”), and Loxo Oncology, Inc., a Delaware corporation (“Loxo”).
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. DRUG DISCOVERY COLLABORATION AGREEMENT BETWEEN GENENTECH, INC. AND CURIS, INC.Drug Discovery Collaboration Agreement • April 29th, 2005 • Curis Inc • Biological products, (no disgnostic substances) • California
THIS DRUG DISCOVERY COLLABORATION AGREEMENT (“Agreement”) is made and entered into, effective as of April 1, 2005 (“Effective Date”), by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Curis Inc., a Delaware corporation, having a principal place of business at 61 Moulton Street, Cambridge, Massachusetts 02138 (“Curis”), (collectively, the “Parties” or individually, a “Party”).
June 30, 2005Drug Discovery Collaboration Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
As you know, InterMune, Inc. (“InterMune”) and Array BioPharma Inc. (“Array”) are parties to that certain Drug Discovery Collaboration Agreement dated September 13, 2002, as amended May 8, 2003, January 7, 2004, September 10, 2004 and December 7, 2004 (collectively, and as further amended pursuant to this letter, the “Agreement”). The parties agree that the Agreement is hereby amended as follows, effective as of the date of this letter (“Amendment Effective Date”):
SECOND AMENDMENT TO DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • February 6th, 2006 • Array Biopharma Inc • Services-medical laboratories
THIS AMENDMENT NO. 2 (“Second Amendment”), effective as of October 1, 2005 (Amendment Date”), is entered into by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”) (collectively, the “Parties” or individually, a “Party”).
AMENDMENT NO. 2 TO DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • August 15th, 2014 • Array Biopharma Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 2 TO DRUG DISCOVERY COLLABORATION AGREEMENT (this “Amendment”) effective as of April 10, 2014 (the “Amendment Date”), is made by and between Array BioPharma Inc., a Delaware corporation (“Array”), and Loxo Oncology, Inc., a Delaware corporation (“Loxo”).
DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • November 14th, 2017 • Colorado
This DRUG DISCOVERY COLLABORATION AGREEMENT (the “Agreement”), effective as of September 13, 2002 (the “Effective Date”), is made by and between AAAA Inc., a ________ corporation, having a principal place of business at ________ (“AAAA”), and IIII, Inc., a ________ corporation, having a principal place of business at ________ (“IIII”).
DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • September 13th, 2005 • Array Biopharma Inc • Services-medical laboratories • Colorado
This DRUG DISCOVERY COLLABORATION AGREEMENT (the “Agreement”), effective as of September 13, 2002 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), and InterMune, Inc., a Delaware corporation, having a principal place of business at 3280 Bayshore Boulevard, Brisbane, California 94005 (“InterMune”).
FIFTH AMENDMENT TO DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • November 4th, 2008 • Array Biopharma Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 5 (“Fifth Amendment”), effective as of September 1, 2008 (“Amendment Date”), is entered into by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), (collectively, the “Parties” or individually, a “Party”).
